All News

The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.

The announcement is set to affect multiple grants awarded to Moderna, which is developing mRNA-1018, a candidate vaccine against avian influenza.

Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.

Sander Kersten, PhD, discusses the distinct roles of ANGPTL3 and ANGPTL4 in lipid metabolism, their interactions with key enzymes, the therapeutic potential of targeting these pathways in lipid-lowering strategies, and important considerations for pharmacists counseling patients on emerging ANGPTL-targeted therapies.

Katherine H. Saunders, MD, DABOM, explores the role of pharmacists in supporting long-term weight management with GLP-1 therapies, including strategies for counseling on lifestyle interventions, managing adverse effects, and ensuring patients receive individualized, evidence-based care.

Researchers explore cellular senescence's role in kidney fibrosis, highlighting potential therapies to combat chronic kidney disease progression.

The test offers health care professionals a simple and efficient method of identifying patients with liver fibrosis of varying severity.

Shore Medical Center enhances patient safety with a pharmacy-driven intravenous to oral opioid conversion protocol, minimizing risks and improving pain management.

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

Two abstracts from the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that pretreatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.

V114, a 15-valent pneumococcal conjugate vaccine (PCV), provided better protection against serotypes 22F and 33F compared with 13-valent PCV (PCV13).

Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.

Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.

Elranatamab shows promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients, highlighting its potential as a treatment option.

The investigators suggest that early detection and treatment of chronic kidney disease (CKD) in childhood cancer survivors may decrease late complications and mortality.

The formulation allows for individualized treatment in children with adrenocortical insufficiency.

New research highlights the significant cardiovascular risks associated with RSV, emphasizing the need for vaccination to protect vulnerable populations.

Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.

Epcoritamab shows impressive long-term remission rates in relapsed large B-cell lymphoma, highlighting its potential as a key treatment option.

FDA approves acoltremon ophthalmic solution, a groundbreaking treatment for dry eye disease, enhancing natural tear production and patient quality of life.

This segment takes a deeper dive into toxicity management—focusing not just on what to monitor, but how institutions are putting these protocols into action in real-world clinical settings.

The FDA approved the MenQuadfi vaccine for young children, enhancing protection against invasive meningococcal disease and its severe complications.

Alice H. Lichtenstein, DSc, emphasizes the importance of whole-food dietary patterns over macronutrient percentages for improving lipid profiles and cardiovascular health.

Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.

Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize treatment in variant carriers.

Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).